Healthcare - Biotechnology - NASDAQ - US
$ 4.19
-2.1 %
$ 249 M
Market Cap
-3.3
P/E
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome.[ Read More ]
The intrinsic value of one PYXS stock under the base case scenario is HIDDEN Compared to the current market price of 4.19 USD, Pyxis Oncology, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart PYXS
FINANCIALS
0
REVENUE
-82.2 M
OPERATING INCOME
-73.8 M
NET INCOME
-70.7 M
OPERATING CASH FLOW
-105 M
INVESTING CASH FLOW
5.93 M
FINANCING CASH FLOW
0
REVENUE
-23.8 M
OPERATING INCOME
-21.2 M
NET INCOME
-14.7 M
OPERATING CASH FLOW
-8 K
INVESTING CASH FLOW
1.72 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Pyxis Oncology, Inc.
| Current Assets | 125 M |
| Cash & Short-Term Investments | 119 M |
| Receivables | 21 K |
| Other Current Assets | 5.28 M |
| Non-Current Assets | 49.1 M |
| Long-Term Investments | 0 |
| PP&E | 24.8 M |
| Other Non-Current Assets | 24.3 M |
| Current Liabilities | 25.8 M |
| Accounts Payable | 3.9 M |
| Short-Term Debt | 2.46 M |
| Other Current Liabilities | 19.4 M |
| Non-Current Liabilities | 22.3 M |
| Long-Term Debt | 20.1 M |
| Other Non-Current Liabilities | 2.16 M |
EFFICIENCY
Earnings Waterfall
Pyxis Oncology, Inc.
| Revenue | 0 |
| Cost Of Revenue | 2 M |
| Gross Profit | -2 M |
| Operating Expenses | 82.2 M |
| Operating Income | -82.2 M |
| Other Expenses | -8.41 M |
| Net Income | -73.8 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-58.70%
ROE
-42.47%
ROA
-64.75%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Pyxis Oncology, Inc.
| Net Income | -73.8 M |
| Depreciation & Amortization | 1.93 M |
| Capital Expenditures | -6.73 M |
| Stock-Based Compensation | 16.9 M |
| Change in Working Capital | -11.7 M |
| Others | -12.3 M |
| Free Cash Flow | -77.4 M |
Wall Street Analysts Price Targets
Pyxis Oncology, Inc.
Wall Street analysts predict an average 1-year price target for PYXS of $9 , with forecasts ranging from a low of $7 to a high of $10 .
PYXS Lowest Price Target
Wall Street Target
7 USD
67.06%
PYXS Average Price Target
Wall Street Target
9 USD
114.80%
PYXS Highest Price Target
Wall Street Target
10 USD
138.66%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Pyxis Oncology, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Sep 28, 2023
|
Bought 15 K USD
|
Connealy Pamela Ann
CFO and COO |
+ 8000
|
1.87 USD |
|
1 year ago
Sep 27, 2023
|
Bought 4.68 K USD
|
Wadhane Jitendra
Chief Accounting Officer |
+ 2500
|
1.87 USD |
|
1 year ago
Sep 27, 2023
|
Bought 11.9 K USD
|
Connealy Pamela Ann
CFO and COO |
+ 6426
|
1.8468 USD |
|
1 year ago
Sep 25, 2023
|
Bought 8.85 K USD
|
Wadhane Jitendra
Chief Accounting Officer |
+ 5000
|
1.77 USD |
|
1 year ago
Sep 25, 2023
|
Bought 20 K USD
|
Connealy Pamela Ann
CFO and COO |
+ 12000
|
1.6703 USD |
|
1 year ago
Sep 22, 2023
|
Bought 4.35 K USD
|
Wadhane Jitendra
Chief Accounting Officer |
+ 2500
|
1.7397 USD |
|
1 year ago
Sep 22, 2023
|
Bought 8.7 K USD
|
Connealy Pamela Ann
CFO and COO |
+ 5000
|
1.739 USD |
|
1 year ago
Sep 14, 2023
|
Sell 225 USD
|
Sullivan Lara
President and CEO |
- 100
|
2.25 USD |
|
1 year ago
Sep 18, 2023
|
Sell 17.9 K USD
|
Sullivan Lara
President and CEO |
- 8541
|
2.1 USD |
|
1 year ago
Sep 11, 2023
|
Sell 45.4 K USD
|
Sullivan Lara
President and CEO |
- 20000
|
2.2707 USD |
|
1 year ago
Sep 12, 2023
|
Sell 11.1 K USD
|
Sullivan Lara
President and CEO |
- 4917
|
2.2516 USD |
|
1 year ago
Sep 13, 2023
|
Sell 6.82 K USD
|
Sullivan Lara
President and CEO |
- 3000
|
2.2719 USD |
|
1 year ago
Mar 17, 2023
|
Bought 5 M USD
|
PFIZER INC
10 percent owner |
+ 1811594
|
2.76 USD |
|
1 year ago
Mar 17, 2023
|
Bought 5 M USD
|
PFIZER INC
10 percent owner |
+ 1811594
|
2.76 USD |
|
2 years ago
Apr 21, 2022
|
Sell 5.32 M USD
|
Chin Mark
director: |
- 1745761
|
3.05 USD |
|
2 years ago
Dec 08, 2021
|
Bought 93.9 K USD
|
Cline Darren S
Director |
+ 10000
|
9.3885 USD |
|
2 years ago
Nov 18, 2021
|
Bought 200 K USD
|
Civik Thomas
Director |
+ 15700
|
12.74 USD |
|
3 years ago
Oct 13, 2021
|
Bought 5 M USD
|
Chin Mark
Director |
+ 312500
|
16 USD |
|
3 years ago
Oct 13, 2021
|
Bought 7.2 M USD
|
Cormorant Asset Management, LP
|
+ 450000
|
16 USD |
7. News
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
Stephens has initiated coverage on Pyxis Oncology Inc PYXS, highlighting the company's technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, stability, and tolerability.
benzinga.com
- 1 week ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ:PYXS) concerning possible breaches of fiduciary duty.
prnewswire.com
- 1 month ago
Moment Of Truth Approaches For Pyxis Oncology
Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024.
seekingalpha.com
- 2 months ago
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in fireside chats and members of management will participate in one-on-one meetings at the following two upcoming investor conferences:
globenewswire.com
- 2 months ago
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected to provide cash runway into the second half of 2026 and enable the Company to fund the next phase of PYX-201 clinical development, which the Company plans to announce in the fall of 2024.
globenewswire.com
- 3 months ago
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, and members of management will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held August 5-6, 2024.
globenewswire.com
- 3 months ago
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology's common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology's common stock to five newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of June 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 4 months ago
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015.
globenewswire.com
- 5 months ago
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings.
globenewswire.com
- 5 months ago
Q2 2024 EPS Estimates for Pyxis Oncology, Inc. (NASDAQ:PYXS) Decreased by Analyst
Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – Investment analysts at HC Wainwright lowered their Q2 2024 earnings estimates for shares of Pyxis Oncology in a research note issued on Thursday, May 16th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.27) per share for the quarter, down from their previous estimate of ($0.12). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.63) EPS, Q1 2025 earnings at ($0.41) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.42) EPS and FY2028 earnings at ($0.70) EPS. A number of other research analysts have also issued reports on PYXS. Royal Bank of Canada restated an “outperform” rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, March 22nd. SVB Leerink initiated coverage on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. They set an “outperform” rating and a $12.00 price target on the stock. BTIG Research initiated coverage on shares of Pyxis Oncology in a research note on Friday, February 9th. They set a “buy” rating and a $8.00 price target on the stock. Leerink Partnrs restated an “outperform” rating on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. Finally, Jefferies Financial Group restated a “buy” rating and set a $10.00 price target on shares of Pyxis Oncology in a research note on Tuesday, May 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $8.80. Read Our Latest Research Report on PYXS Pyxis Oncology Stock Down 0.5 % NASDAQ:PYXS opened at $4.15 on Monday. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The firm has a 50 day moving average of $4.68 and a 200 day moving average of $3.54. The stock has a market capitalization of $244.39 million, a price-to-earnings ratio of -3.05 and a beta of 1.45. Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last posted its earnings results on Saturday, May 11th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The firm had revenue of $16.15 million for the quarter, compared to analysts’ expectations of $4.25 million. Institutional Trading of Pyxis Oncology Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Decheng Capital Management III Cayman LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $650,000. abrdn plc acquired a new stake in Pyxis Oncology during the fourth quarter valued at $1,275,000. Acadian Asset Management LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $26,000. Commonwealth Equity Services LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $26,000. Finally, Schulhoff & Co. Inc. acquired a new stake in Pyxis Oncology during the third quarter valued at $44,000. Institutional investors and hedge funds own 39.09% of the company’s stock. About Pyxis Oncology (Get Free Report) Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. See Also Five stocks we like better than Pyxis Oncology What Does a Stock Split Mean? MarketBeat Week in Review – 5/13 – 5/17 What does consumer price index measure? Take-Two Interactive Software Offers 2nd Chance for Investors 3 Fintech Stocks With Good 2021 Prospects Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
https://www.defenseworld.net
- 5 months ago
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
Pyxis Oncology, Inc. (PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago.
zacks.com
- 6 months ago
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target, has dosed 42 patients in 8 cohorts since initiating the Phase 1 trial in March 2023 with continued enthusiasm for this agent by global investigators.
globenewswire.com
- 6 months ago
8. Profile Summary
Pyxis Oncology, Inc. PYXS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 249 M
Dividend Yield
0.00%
Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Contact
35 Cambridgepark Drive, Cambridge, MA, 02140
https://www.pyxisoncology.com
IPO Date
Oct. 8, 2021
Employees
54
Officers
Dr. Lara S. Sullivan M.D., MBA
Chief Executive Officer, President & Director
Dr. Charles T. Gombar Ph.D.
Senior Vice President of Portfolio & Program Management
Mr. Stephen T. Worsley MBA
Senior Vice President & Chief Business Officer
Dr. Jan Pinkas Ph.D.
Chief Scientific Officer
Ms. Pamela Yanchik Connealy M.B.A.
Chief Financial Officer & Chief Operating Officer
Mr. Jitendra Wadhane
Chief Accounting Officer, Senior Vice President of Finance & Corporate Controller
Dr. Balu N. Balasubramanian Ph.D.
Interim Chief Technology Officer
Dr. Ken Kobayashi FACP, M.D.
Chief Medical Officer